BioCryst Pharmaceuticals, Inc., a prominent entity in the biotechnology sector, operates within the broader Health Care industry. The company is headquartered in Durham, United States, and is publicly traded on the Nasdaq stock exchange. BioCryst Pharmaceuticals is dedicated to discovering novel, oral, small-molecule medicines aimed at treating rare diseases where enzymes play a crucial role in the biological pathways of these conditions. By addressing significant unmet medical needs, the company extends its services to a global clientele.
As of the latest update on January 13, 2026, BioCryst Pharmaceuticals has not reported any new developments. The most recent public communication was a transcript from the JPMorgan Healthcare Conference. The company’s stock closed at $7.17 on January 14, 2026, positioning it approximately in the middle of its recent trading range. Over the past year, the stock has experienced a high of $11.31 on June 3, 2025, and a low of $6.00 on October 13, 2025. This indicates a moderate level of volatility, with a spread of about $5.31.
Currently, the stock price is approximately $2.14 below its 52-week high and $1.17 above its 52-week low, suggesting that it is trading closer to the lower end of its recent range. No additional corporate actions or market events have been reported in the available data. BioCryst Pharmaceuticals was initially public through an IPO on March 3, 1994. The company’s market capitalization stands at approximately $1.51 billion USD, reflecting its valuation in the biotechnology sector.
For further information on BioCryst Pharmaceuticals’ work and offerings, interested parties can visit their official website at www.biocryst.com .
